Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infectionSARS-CoV-2 델타 변이형 감염 고위험 환자의 질병 중증도 결과에 대한 카시리비맙-임데비맙 치료의 의심스러운 임상 이점Article Published on 2022-06-012022-09-11 Journal: European journal of internal medicine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Abstract BNT162b2 BNT162b2 vaccine Casirivimab Casirivimab/Imdevimab therapy clinical benefit disease severity high-risk patient High-risk patients Imdevimab Infection outcome SARS-CoV-2 delta SARS-CoV-2 Delta variant severe outcome Treatment variant [DOI] 10.1016/j.ejim.2022.03.001 PMC 바로가기 [Article Type] Article
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fallArticle Published on 2022-06-012023-07-08 Journal: Expert opinion on drug discovery [Category] COVID19(2023년), [키워드] Casirivimab Imdevimab REGEN-COV REGN-CoV-2 Ronapreve [DOI] 10.1080/17460441.2022.2058486
High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COVREGN-COV로 중화 항체 칵테일 요법을 받는 환자 중 SARS-CoV-2 스파이크 단백질에 대한 높은 항체가Article Published on 2022-06-012022-09-11 Journal: Infection [Category] COVID19(2023년), SARS, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration antibody Antibody titer Antibody titers Architect body weight Casirivimab casirivimab/imdevimab clinical benefit cocktail collected coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 effective elevated evaluated IgG Imdevimab Immunoglobulin Linear regression model median Neutralizing antibodies neutralizing antibody nine nucleocapsid protein Patient patients with COVID-19 Prophylactic Prophylaxis receiving Receptor-binding domain REGN-COV remained respiratory SARS-CoV-2 SARS-CoV-2 IgG serological serological data severe acute respiratory syndrome Coronavirus shown simple linear regression Spike protein Support the receptor-binding domain the SARS-CoV-2 therapeutic therapy treated Treatment were assessed [DOI] 10.1007/s15010-022-01779-x PMC 바로가기 [Article Type] Article
Therapeutic monoclonal antibodies for COVID-19 management: an updateReview Published on 2022-06-012023-07-09 Journal: Expert opinion on biological therapy [Category] COVID19(2023년), [키워드] bamlanivimab bebtelovimab Casirivimab clinical trial COVID-19 etesevimab Imdevimab monoclonal antibody repurposed mAbs SARS-CoV-2 tixagevimab with cilgavimab. [DOI] 10.1080/14712598.2022.2078160 [Article Type] Review
A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab새로운 인간 중화 mAb는 SARS-CoV-2의 델타, 감마 및 오미크론 변이체를 인식하고 소트로비맙과 함께 사용할 수 있습니다Article Published on 2022-05-162022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ACE-2 ACE-2 receptor angiotensin angiotensin converting enzyme anti-spike MAbs antibody Can Casirivimab caused Cell culture cell cultures cell entry Clinical use combinatorial treatment combinatorial treatments coronavirus Delta diagnostic drug ENhance epidemics/pandemics epitope Epitopes Gamma glycoprotein Human Imdevimab immune system Infection inhibitory effect Interaction interfere investigated mAb mAbs monoclonal monoclonal antibodies Neutralizing Neutralizing activity neutralizing mAbs. novel omicron Omicron variant pandemic Pandemics Patient RBD Receptor binding domain recognize recognizing SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 virus Scientific community Sotrovimab spike spike glycoprotein Spike-RBD/ACE-2 subsequent the antibody the Spike therapeutic therapy variants virus virus infection [DOI] 10.3390/ijms23105556 PMC 바로가기 [Article Type] Article
Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic델타 변이형 대유행 기간 동안 경증에서 중등도의 코로나바이러스 질환 환자를 대상으로 한 카시리비맙-임데비맙 치료의 실제 임상 결과Article Published on 2022-05-092022-09-11 Journal: International Journal of Medical Sciences [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Admission body temperature Casirivimab casirivimab-imdevimab cigarette smoking clinical Clinical deterioration Clinical outcome contribute coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient Delta delta variant demonstrated Deterioration dyslipidemia Effectiveness Efficacy enrolled evaluated Fukushima greater hospital Hospitalization hypertension Imdevimab independent Japan Logistic regression analysis Mild-to-moderate monoclonal antibody monoclonal antibody therapy multivariate multivariate logistic regression analysis Neutralizing obesity Odds ratio Older pandemic Patient Propensity score real-world effectiveness. receiving reduce respiratory SARS-CoV-2 selected severe acute respiratory syndrome Coronavirus significantly lower smoking therapy Treatment [DOI] 10.7150/ijms.71132 PMC 바로가기 [Article Type] Article
Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 20192019년 경증에서 중등도의 코로나바이러스 질환이 있는 고위험 환자의 밤라니비맙-에테세비맙 및 카시리비맙-임데비맙 치료 후 심각한 결과의 비율Article Published on 2022-05-012022-09-11 Journal: Mayo Clinic proceedings [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus Alpha bamlanivimab Casirivimab Clinical characteristics Clinical efficacy Clinical outcome clinical outcomes clinical study Cohort cohorts of patient coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 demographic and clinical characteristics drug Efficacy emergency treatment etesevimab food higher odd higher odds Hospitalization Imdevimab Mild mild to moderate Mild to moderate COVID-19 moderate Moderate COVID-19 monoclonal antibodies monoclonal antibody not significantly different observation Odds ratio outcome oxygen oxygen supplementation Patient progression Rate reason respiratory Retrospective study severe acute respiratory syndrome Coronavirus significant difference significantly higher treated Treatment US Food and Drug Administration variants wild-type [DOI] 10.1016/j.mayocp.2022.02.009 PMC 바로가기 [Article Type] Article
Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19COVID-19로 입원하지 않은 환자의 조기 치료를 위한 Casirivimab/Imdevimab 및 Bamlanivimab/Etesevimab의 효과를 비교하기 위한 관찰 데이터의 표적 시험 에뮬레이션Clinical Trial Published on 2022-04-202022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adjusted allocation Alpha Analysis ANCOVA bamlanivimab bamlanivimab/etesevimab baseline carried Casirivimab casirivimab/imdevimab Combination Comparative analysis COVID-19 Cox model Ct value cycle threshold death Delta determine early treatment early treatment for COVID-19 Effectiveness enrolment etesevimab evaluated Evidence Factor Factors high viral load Hospitalization Imdevimab in viral Intervention Logistic regression mAb mAbs Mild-to-moderate Model Modification monoclonal antibodies monoclonal antibody Nasopharyngeal swab negative RT-PCR not used Observational data occurred outcome Outpatient outpatients Patient PCR test Primary outcome Probability progression reduced risk reduction Relative risk risk reduction RT-PCR test SARS-CoV-2 Stratification subject target Treatment Trial two group two groups vaccination variants variants of concern Viral Viral load viral load reduction virological response VOCs was measured was used were used [DOI] 10.3389/fimmu.2022.868020 PMC 바로가기 [Article Type] Clinical Trial
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19카시리비맙 및 임데비맙 단클론항체의 피하 또는 정맥내 투여와 COVID-19가 있는 성인의 임상 결과와의 연관성Article Published on 2022-04-012022-09-12 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI adjusted administer Administered administration Admission adverse events age antibody association Casirivimab clinical clinically cohort study Control control group COVID-19 death decrease eligible eligible patient Emergency use authorization end point evaluate evaluated Evidence expand health system Hospitalization Imdevimab injection intensive care intravenous mAb mechanical ventilation Mild moderate Moderate COVID-19 no difference outcome Outpatient Patient patients patients treated Primary outcome prospective cohort study randomized clinical trial reduced risk risk ratio secondary single dose statistically Subcutaneous subcutaneous administration subcutaneously Symptom Symptoms Treatment women [DOI] 10.1001/jamanetworkopen.2022.6920 PMC 바로가기 [Article Type] Article
Immune treatment in COVID-19COVID-19의 면역 치료Review Published on 2022-04-012022-09-11 Journal: Revista española de quimioterapia : publicación [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] apparition bamlanivimab Casirivimab cells clinical benefit Combination convalescent plasma COVID-19 current doses etesevimab Evolution exhibited Imdevimab immune knowledge mAb mAbs Meta-analysis meta-analysis and systematic review monoclonal antibodies monoclonal antibody Neutralizing activity omicron Omicron variant Patient progression Recombinant protein recombinant proteins reduction in reported retained SARS-CoV-2 serological shown Sotrovimab Standard of care systematic review target population the disease Treatment variant variants Viral Viral load viral replication [DOI] 10.37201/req/s01.14.2022 PMC 바로가기 [Article Type] Review